CochLear Ltd. Unsponsored ADR (OTCMKTS:CHEOY – Get Free Report) shares gapped up prior to trading on Thursday. The stock had previously closed at $49.10, but opened at $54.00. CochLear shares last traded at $53.76, with a volume of 323 shares trading hands.
Analyst Ratings Changes
A number of equities research analysts have weighed in on CHEOY shares. Royal Bank Of Canada lowered CochLear from an “outperform” rating to a “sector perform” rating and set a $117.00 price objective for the company. in a research note on Thursday, July 16th. Jefferies Financial Group cut CochLear from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, July 22nd. Finally, Canaccord Genuity Group downgraded shares of CochLear from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 18th. Five investment analysts have rated the stock with a Hold rating. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $117.00.
View Our Latest Stock Report on CHEOY
CochLear Price Performance
The business’s 50 day moving average price is $48.30 and its 200-day moving average price is $51.83.
About CochLear
Cochlear Limited is an Australian medical device company that develops, manufactures and supplies implantable hearing solutions for people with moderate to profound hearing loss. Its portfolio includes cochlear implants, bone conduction implants and related sound processors, accessories and connectivity products designed to help users hear in a range of environments.
The company also provides clinical support, rehabilitation resources, software, technical services and ongoing care for recipients, clinicians and hearing professionals.
See Also
- Five stocks we like better than CochLear
- Astera Labs Just Crushed Earnings—So Why Are Analysts Cutting Price Targets?
- Sandisk Shares Are Oversold: Bargain or Value Trap?
- IonQ’s Record Revenue Includes a Big SkyWater Boost: Does That Change the Story?
- Airbnb Defied a Brutal Tech Sell-Off, But Can Its Post-Earnings Rally Last?
Receive News & Ratings for CochLear Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CochLear and related companies with MarketBeat.com's FREE daily email newsletter.
